Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Non-Current Liabilities (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Total Non-Current Liabilities data on record, last reported at $46.4 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 17.29% year-over-year to $46.4 million; the TTM value through Dec 2025 reached $46.4 million, down 17.29%, while the annual FY2025 figure was $46.4 million, 17.29% down from the prior year.
  • Total Non-Current Liabilities reached $46.4 million in Q4 2025 per ACRS's latest filing, up from $44.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $60.2 million in Q3 2023 and bottomed at $18.0 million in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $38.3 million, with a median of $44.3 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: crashed 66.57% in 2024, then surged 207.81% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $25.5 million in 2021, then dropped by 6.26% to $23.9 million in 2022, then surged by 42.52% to $34.0 million in 2023, then surged by 64.79% to $56.1 million in 2024, then dropped by 17.29% to $46.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $46.4 million in Q4 2025, $44.8 million in Q3 2025, and $55.6 million in Q2 2025.